Most Clicked StoriesMore >


Valeant's plaque psoriasis drug approved by FDA

BIO SmartBrief | Feb 16, 2017

Valeant Pharmaceuticals' injectable biologic Siliq, or brodalumab, has been approved by the FDA as a treatment for moderate to severe plaque psoriasis in adults who are eligible for phototherapy or systemic therapy and did not or no longer respond to other systemic treatments. Medscape (free registration) (02/15) Reuters (02/15)


Drug industry groups warn against big changes at FDA

BIO SmartBrief | Feb 16, 2017

Immunomedics, Seattle Genetics sign $2B licensing deal for cancer ADC

BIO SmartBrief | Feb 13, 2017

Incyte, Eli Lilly's rheumatoid arthritis drug gets EU nod

BIO SmartBrief | Feb 14, 2017

Janssen, Akebia sign licensing deal for HIF candidates

BIO SmartBrief | Feb 15, 2017

Administration signals support for federal "right to try" measure

BIO SmartBrief | Feb 13, 2017

IPO brings in $51.1M for Inventiva

BIO SmartBrief | Feb 16, 2017

Gilead grants Amygdala license to substance abuse candidate

BIO SmartBrief | Feb 17, 2017

Inovio signs deal with ApolloBio to develop HPV vaccine in China

BIO SmartBrief | Feb 14, 2017

Biosimilar cancer drugs being reviewed in Europe

BIO SmartBrief | Feb 17, 2017


Find BIO SmartBrief Issues by Date:



BIO News More >


BIO Asia International Conference

BIO SmartBrief | Feb 17, 2017

Registration is open for the 2017 BIO Asia International Conference

BIO SmartBrief | Feb 17, 2017

All the tools you need to communicate your financial news

BIO SmartBrief | Feb 16, 2017

UPS

BIO SmartBrief | Feb 15, 2017

Registration for BIO 2017 World Congress now open

BIO SmartBrief | Feb 14, 2017




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more